Prognostic Significance of Preoperative Nutritional Status on Postoperative Acute Kidney Injury

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age65-100
SponsorWanmin Liao

About this trial

The incidence of postoperative acute kidney injury (AKI) is high in patients undergoing lung resection surgery, especially in the elderly. Early identification of high-risk postoperative AKI patients can help develop prevention and treatment management strategies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

aged ≥ 65 years

lung resection surgery including:pneumonectomy , bilobectomy , lobectomy, segmentectomy, wedge resection/bullectomy.

Disqualifiers

patients with an American Society of Anesthesiologists (ASA) physical status V.

those with end-stage renal disease (i.e. a glomerular filtration rate of 15 mL/min/1.73 m2 or receiving haemodialysis).

those did not have sufficient data required for nutritional evaluation or AKI evaluation.

Trial population

Older patients (aged ≥ 65 years) who underwent lung resection surgery under general anesthesia at our Hospital between January 2020 and June 2024 were included in our study. Lung resection surgery included pneumonectomy , bilobectomy , lobectomy, segmentectomy, wedge resection/bullectomy.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • no intervention

    Other intervention

    no intervention

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Postoperative acute kidney injury

In accordance with the KDIGO creatinine criteria: a serum creatinine increases of 26.5 mmol/L within 48 hours or 1.5 times baseline within 7 days after surgery.

Time frame
Within 7 days after surgery

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Wanmin Liao

Lead sponsor

Tongji Hospital

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: